« Return to News | Drug Sponsors

Arrowhead enters into antibody candidate evaluation agreement with Merck

Wednesday, August 15, 2012 11:27 AM

Arrowhead Research, a clinical stage targeted therapeutics company based in Pasadena, Calif., has entered into an agreement with global healthcare company Merck, through a subsidiary, to undertake an evaluation of a novel proprietary therapeutic monoclonal antibody candidate derived from Arrowhead’s human-derived peptide targeting and discovery program.

Arrowhead acquired the program through its purchase of Alvos Therapeutics in April 2012. Merck will bear the costs involved in evaluating the candidate.

“We are excited to be working with Merck as they evaluate this antibody candidate,” said Dr. Chris Anzalone, president and CEO of Arrowhead. “We believe that our human-derived library of targeting peptides and novel receptors is the world’s largest and can be used with many classes of drugs across multiple indications to enhance efficacy and decrease side effects.”

Arrowhead’s target discovery and delivery platform consists of a large library of unique human-derived peptide sequences selected for their ability to bind cell surface targets and rapidly internalize within cells of more than 30 distinct tissues and multiple tumor types. The discovery process, which involves screening directly in human patients under strict ethical guidelines, has identified novel receptor targets as well as novel binding sites for validated targets. Additional antibody and peptide-based targeting programs for oncology and other therapeutic areas are currently being identified and assessed for internal development or partnering.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.